Changes in 18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?
P
P
Price
D000970:Antineoplastic Agents / Q000627:therapeutic use; D005060:Europe; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000378:metabolism; D017410:Practice Guidelines as Topic; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals / Q000378:metabolism; D012680:Sensitivity and Specificity; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed / Q000379:methods
D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005947:Glucose